Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GSK4532990
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial
Details : Under the collaboration, the trial will measure improvements in liver histology with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : GSK4532990
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Resmetirom
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PathAI To Present Three Abstracts at International Liver Congress 2022
Details : Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Resmetirom
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results from the study indicated that via both manual and AI assessment, NASH resolution was dose dependent, with a higher proportion of patients receiving semaglutide 0.4mg achieving NASH resolution without fibrosis worsening, compared to patients r...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 11, 2021
Lead Product(s) : Semaglutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable